NEPTUNUS(SZ:000078) Sou Hu Cai Jing·2025-08-02 02:10Core Points - The stock price of Haiwang Bio (000078) closed at 2.8 yuan on August 1, 2025, with an increase of 1.82% and a trading volume of 856,100 shares, amounting to 242 million yuan in transaction value [1] - The company reported a total revenue of 7.376 billion yuan for Q1 2025, a year-on-year decrease of 8.81%, and a net profit attributable to shareholders of 23.72 million yuan, down 44.38% year-on-year [1] - Haiwang Bio has a current ratio of 1.022, a quick ratio of 0.889, and a debt-to-asset ratio of 89.76% [1] Financial Performance - Total revenue for Q1 2025: 7.376 billion yuan, down 8.81% year-on-year [1] - Net profit attributable to shareholders: 23.72 million yuan, down 44.38% year-on-year [1] - Non-recurring net profit: 74.74 million yuan, down 257.78% year-on-year [1] - Current ratio: 1.022 [1] - Quick ratio: 0.889 [1] - Debt-to-asset ratio: 89.76% [1] Market Activity - Main capital inflow on the reporting day was 13.96 million yuan, accounting for 5.77% of the transaction value [1] - Large orders saw a net inflow of 9.36 million yuan, representing 3.87% of the transaction value [1] - Small orders experienced a net outflow of 14.71 million yuan, which is 6.08% of the transaction value [1] Company Overview - Haiwang Bio was established in 1992 and is located in Shenzhen, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has invested in 20 enterprises and holds 14 administrative licenses [2] - Registered capital: 2.631 billion yuan [2]